David K Hooper

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. pmc Reliable individualized monitoring improves cholesterol control in kidney transplant recipients
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, MLC 7022, 3333 Burnet Ave, Cincinnati, OH 45229, USA
    Pediatrics 131:e1271-9. 2013
  2. doi Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, James M Anderson Center for Health Systems Excellence, Cincinnati, OH 45229, USA
    Pediatr Transplant 15:88-95. 2011
  3. doi Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Transplantation 93:806-12. 2012
  4. pmc The influence of context on quality improvement success in health care: a systematic review of the literature
    Heather C Kaplan
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Milbank Q 88:500-59. 2010
  5. pmc Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period
    Min Dong
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Br J Clin Pharmacol 78:1102-12. 2014
  6. pmc The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Pediatr Nephrol 28:939-49. 2013

Collaborators

Detail Information

Publications6

  1. pmc Reliable individualized monitoring improves cholesterol control in kidney transplant recipients
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, MLC 7022, 3333 Burnet Ave, Cincinnati, OH 45229, USA
    Pediatrics 131:e1271-9. 2013
    ..To develop and evaluate a system for reliable and efficient individualized risk-based monitoring of cholesterol and 11 other tests after kidney transplantation in children...
  2. doi Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, James M Anderson Center for Health Systems Excellence, Cincinnati, OH 45229, USA
    Pediatr Transplant 15:88-95. 2011
    ..In multivariate analysis, only CIVN significantly predicted AEI (AOR 2.8, 95% CI 1.29-6.04). Thus, until clinical studies to fully characterize this interaction are completed, CIVN should be used with caution in TAC-treated individuals...
  3. doi Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Transplantation 93:806-12. 2012
    ....
  4. pmc The influence of context on quality improvement success in health care: a systematic review of the literature
    Heather C Kaplan
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Milbank Q 88:500-59. 2010
    ..The mixed results of success among QI initiatives may be due to differences in the context of these initiatives...
  5. pmc Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period
    Min Dong
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Br J Clin Pharmacol 78:1102-12. 2014
    ..The purpose of this study was to develop a population pharmacokinetic and pharmacodynamic (PK-PD) model for mycophenolic acid (MPA) in paediatric renal transplant recipients in the early post-transplant period...
  6. pmc The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Pediatr Nephrol 28:939-49. 2013
    ..Cardiovascular disease is the leading cause of increased mortality for adolescents with advanced kidney disease. The quality of preventive cardiovascular care may impact long-term outcomes for these patients...